SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Neovacs SA: New Promising Data in the Phase I/II Clinical Trial in Lupus Patients: Data from the Last Cohort of Patients (240 Mcg) Confirm the Safety, Immunogenicity and Pharmacodynamic of IFN-K